Table 3.
Reference | Year of study | Country | n/N (%) Received Pneumococcal vaccine | Comments |
---|---|---|---|---|
10 | 2013 | 22 countries | 230/5235 (4.4) | overall rate |
29 | 2004 | Iran | 750/30037 (2.5) | overall rate |
29 | 2005 | Iran | 6735/75676 (8.9) | overall rate |
31 | 2012 | France | 22/46 (47.8) | * at risk |
40 | 2009 | France | 86/274 (31.4) | overall rate |
44 | 2011 | Australia | 49/158 (30.6) | * at risk |
44 | 2012 | Australia | 95/513 (45.3) | * at risk |
44 | 2013 | Australia | 31/219 (29) | * at risk |
54 | 2011 | France | (5) | overall rate |
60 | 2010 | France | (5) | * at risk |
61 | 2005 | United Kingdom | (15) | overall rate |
At risk: age ≥65 years, smoker, comorbid medical conditions (chronic lung, heart, liver, kidney, neuromuscular, metabolic)